US3883647A - Tablet formulation - Google Patents
Tablet formulation Download PDFInfo
- Publication number
- US3883647A US3883647A US312469A US31246972A US3883647A US 3883647 A US3883647 A US 3883647A US 312469 A US312469 A US 312469A US 31246972 A US31246972 A US 31246972A US 3883647 A US3883647 A US 3883647A
- Authority
- US
- United States
- Prior art keywords
- tablet
- weight
- tablets
- percent
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000007916 tablet composition Substances 0.000 title description 9
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 238000009472 formulation Methods 0.000 claims abstract description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 5
- 229960000201 isosorbide dinitrate Drugs 0.000 claims description 5
- 239000004606 Fillers/Extenders Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 91
- 235000013350 formula milk Nutrition 0.000 description 29
- 239000000314 lubricant Substances 0.000 description 11
- 238000013461 design Methods 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 9
- 238000007907 direct compression Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007910 chewable tablet Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004049 embossing Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
Definitions
- ABSTRACT Primary Examiner-Shep K. Rose Attorney, Agent, or Firm-Joseph Martin Weigman ⁇ 57] ABSTRACT The disclosure is directed to formulations for tablets which are to be deeply grooved to facilitate breaking into predetermined portions by the user. A critical tablet weight for deeply grooved tablets is disclosed.
- a groove, or bisect, or score may be formed on one of the tablet faces.
- the groove facilitates breaking of the tablet into two parts by applying pressure while the tablet is held between two fingers or in both hands.
- dividing a tablet into two or more accurate predetermined parts permits the administration of two or more doses of the active ingredient, or drug, contained in the tablet.
- Potent drugs are frequently incorporated in small amounts into a total tablet formulation, and the capability to divide the tablet accurately allows for a saving by not having to formulate, package and distribute different sized tablets for a portion of the dose and for the full dose.
- the inclusion of one-half of that dose in a tablet of similar size decreases the relation of drug to excipients twofold, thus in many cases also increasing the possibility of drug degradation due to drugexcipient interaction.
- FIG. 1 is an isometric view of a pharmaceutical tablet employing a deeply scored design
- FIG. 2 is a top plan view thereof
- FIG. 3 is a side elevational view thereof as seen at right angles to FIG. 2;
- FIG. 4 is an end elevational view thereof as seen at right angles to FIG. 2;
- FIG. 5 is an end elevational view of a pharmaceutical tablet embodying a modification of the form illustrated in FIG. 4;
- FIG. 6 is a bottom view of the embodiments of FIGS. 1 and 5.
- the deeply grooved tablet design presents tablet compression characteristics which are not typical of the manufacturing of conventional pharmaceutical tab lets. While tablets are usually compacted between uniform surfaces, flat or concave, the deeply grooved tablet design presents a non-uniform compressing surface on one tablet face and a uniform face, spherical or flat, on the other.
- Such a multiplanar surface presents a process of physical compaction which does not produce the results expected from a conventional compressed tablet. In the process of compaction, the multiplanar surface applies forces, the resultant of which is not vertical. This results in non-uniform stress distribution within the tablet as an independent unit which in turn causes tablet capping and the inadequate imprinting or embossing of indicia of any of its surfaces.
- the uneven distribution of stresses results in varying levels oflubrication effectiveness of the tablet planes in contact with the press tooling which, in turn, causes picking" of material off the tablet surface.
- To overcome this phenomenon requires a highly cohesive mixture which is at the same time sufficiently lubricated to enable friction-free tooling to tablet contact on all tablet planes.
- the tablet formulator has to balance the lubricant level against the binder level because the increase of the former will diminish the effect of the latter until the critical region of such action is surpassed.
- This invention has been directed principally to the application of specific pharmaceutical formulations incorporating isosorbide dinitrate as the active ingredient, but is applicable to other deeply grooved tablets as well.
- lsosorbide dinitrate is a potent coronary vasodilator.
- compositions containing the active ingredient would tablet in an acceptable manner because acceptable tablets could be made at this composition using conventional tools.
- a critical binder-lubricant relationship was needed to produce acceptable tablets with deep scoring tooling.
- the experiments are shown in Example ll:
- FORMULA B contained the minimal level of anhydrous lactose to produce an adequate tablet. However, the tablet demonstrated poor disintegration.
- FORMULA C produced soft tablets that capped while still picking.
- FORMULA E showed insufficient binding resulting in very soft tablets having high friabilityl FORMULA F showed inadequate performance because of slight pick.
- FORMULA G showed adequate manufacturability as to hardness and friability.
- the tablets were free of pick ing.
- the preferred weight for deeply grooved tablets is 150 to 175 mg.
- the preferred ratio of lubricant to binder is obtained when the binder constitutes 45 to 99.7 w/o and the lubricant constitutes 0.3 to 0.4 w/o of tablet exclusive of the amount of the active ingredient, fillers, extenders. flavor and the like. That is, the weight per cent of the binder and lubricant is based on the portion of the tablet composition usually referred to as q.s.
- a particularly advantageous formula weighs 175 mg. per tablet and contains 60 percent by weight microcrystalline cellulose with 0135 percent by weight of magnesium stearate.
- Formula A exhibited very high friability. capping and a narrow hardness range.
- Formula C was a wet granulated formula, and exhibited high friability, capping and inadequate chewability due to the wet binder.
- Formula D shows adequate manufacturability and chewability.
- Formula G was slugged and exhibited capping, narrow hardness range and slight picking.
- Formula H produced adequate tableting characteristics.
- the first formulation uses a directly compressed mannitol and a dextrose and corn syrup solids granulation in combination;
- the second formulation uses dextrose and corn syrup solids granulation without mannitol in direct compression.
- the preferred embodiment at which chewable deeply scored tablets can be made is for the first category with at least 20 percent by weight of microcrystallinc cellulose, 31.5 percent by weight of Cellutab anhydrous. 25 percent mannitol and a range of 0.7-1.0 percent by weight of magnesium stearate Jr: at the second category with Cellutab anhydrous and a minimum of 0.35 percent by weight of magnesium stearatc.
- Table II present the compositions of pharmaceutical tablets manufactured by three basic methods: direct compression. dry granulation, and wet granulation. These examples are not to be construed as limiting the scope of this invention which may only be determined by reference to the appended claims.
- a pharmaceutical tablet which is adequately imprinted with indicia or embossing and scored to form a groove which is one-third to two-thirds the depth of the total tablet thickness to facilitate separation into subdivisions containing substantially equal amounts of a pharmaceutically active ingredient comprising a directly compressed formulation of 5 to 10 milligrams of an active ingredient, the remainder being 45 to 99.7 percent by weight of microcrystalline cellulose and 0.3 to 0.4 percent by weight of magnesium stearate, along with fillers. extenders, flavoring and the like.
- a tablet as defined in claim 1 in which the total tablet weight is about l milligrams 4.
- a tablet as defined in claim 1 in which the microcrystalline cellulose is present in the amount of 60 percent by weight and the magnesium stearate is present in the amount of 0.35 percent by weight.
Abstract
The disclosure is directed to formulations for tablets which are to be deeply grooved to facilitate breaking into predetermined portions by the user. A critical tablet weight for deeply grooved tablets is disclosed.
Description
United States Patent 1 Geller [4 1 May 13, 1975 TABLET FORMULATION [75] Inventor: Ehud Geller, King of Prussia, Pa.
[73] Assignee: Ives Laboratories, New York, N.Y.
[22] Filed: Dec. 6, 1972 [21] Appl. No.: 312,469
[52] US. Cl. 424/15; 424/362, 424/6 [51] Int. Cl A61] 3/10; A6lk 9/00 [58] Field of Search 424/15, 6, 362
[56] References Cited UNITED STATES PATENTS 1,836,604 12/1931 Meyer 127/30 3,146,168 8/1964 Battista 424/362 3,336,200 8/1967 Krause et a1... 424/19 3,723,614 3/1973 Langauer 424/15 D9l,644 3/1934 Blackstone D16/3 D201,497 6/1965 Ninger D1613 D202,467 10/1965 Guilmot D1613 FOREIGN PATENTS OR APPLICATIONS 1,200,790 9/1965 Germany 352,208 9/1937 Italy 6,614,61 l 4/1967 Netherlands OTHER PUBLICATIONS Reier et al., J. Pharm. Sci. 55(5), 510-514, (1966), Microcrystalline Cellulose in Tableting." Reier, Dissertation Abtr. 25(5), 2933 (1964), Microcrystalline Cellulose in Tableting." Fox et al., Cosmetic Ind. 92, 161-164, 258-261, (1963), Microcrystalline Cellulose in Tabletting." Battista et al., Ind. Eng. Chem. 54(9), 20-29, (1962), Microcrystalline Cellulose. Woods, Am. Perfumer Cosmet. 80(4), 51-53, 55-60, (1965), Microcrystalline Cellulose, A New Ingrediem for Pharmaceuticals and Cosmetics."
Primary Examiner-Shep K. Rose Attorney, Agent, or Firm-Joseph Martin Weigman {57] ABSTRACT The disclosure is directed to formulations for tablets which are to be deeply grooved to facilitate breaking into predetermined portions by the user. A critical tablet weight for deeply grooved tablets is disclosed.
5 Claims, 6 Drawing Figures TABLET FORMULATION This invention relates to novel formulations for tablets which are to be deeply grooved. Deeply grooved tablets are those in which the groove is one-third to two-thirds of the total tablet thickness. Such tablets are shown for instance in U.S. Pat. No. 224,591 and in copending applications Ser. No. 386,l42 filed Aug. 6, I973 which is a continuation-in-part of Ser. No. 312,065 filed Dec. 4, I972 and now abandoned which was in turn a combination of Ser. No. ll4,926 filed Feb. 12, 1971 and Ser. No. 124,894 filed Mar. 16, I971. The foregoing patent and applications were all filed by Edwin F. Roberts and assigned to the assignee of this application. The tablet design allows for easy, simple and accurate division of a pharmaceutical tablet.
in the manufacture of tablets a groove, or bisect, or score, may be formed on one of the tablet faces. The groove facilitates breaking of the tablet into two parts by applying pressure while the tablet is held between two fingers or in both hands.
In the pharmaceutical industry dividing a tablet into two or more accurate predetermined parts permits the administration of two or more doses of the active ingredient, or drug, contained in the tablet. Potent drugs are frequently incorporated in small amounts into a total tablet formulation, and the capability to divide the tablet accurately allows for a saving by not having to formulate, package and distribute different sized tablets for a portion of the dose and for the full dose. In addition, it is often beneficial to the chemical stability of the drug to incorporate the full dose in the smallest tablet size available. The inclusion of one-half of that dose in a tablet of similar size decreases the relation of drug to excipients twofold, thus in many cases also increasing the possibility of drug degradation due to drugexcipient interaction.
Some of the problems that arise in the production of regularly grooved tablets are:
l. Depending on its hardness, it is sometimes impossible to break the tablet although it is scored.
2. Scores do not always assure precise division of the tablet.
3. Pharmaceutical tablets of smaller sizes do not allow for ease of holding and breaking; in which case the patient very often resorts to using other means of dividing the tablet which results in losing parts of it or obtaining uneven parts or both.
Typical deeply scored tablets to which the present invention is applicable are shown in the drawings in which:
FIG. 1 is an isometric view ofa pharmaceutical tablet employing a deeply scored design;
FIG. 2 is a top plan view thereof;
FIG. 3 is a side elevational view thereof as seen at right angles to FIG. 2;
FIG. 4 is an end elevational view thereof as seen at right angles to FIG. 2;
FIG. 5 is an end elevational view ofa pharmaceutical tablet embodying a modification of the form illustrated in FIG. 4; and
FIG. 6 is a bottom view of the embodiments of FIGS. 1 and 5.
The deeply grooved tablet design presents tablet compression characteristics which are not typical of the manufacturing of conventional pharmaceutical tab lets. While tablets are usually compacted between uniform surfaces, flat or concave, the deeply grooved tablet design presents a non-uniform compressing surface on one tablet face and a uniform face, spherical or flat, on the other. Such a multiplanar surface presents a process of physical compaction which does not produce the results expected from a conventional compressed tablet. In the process of compaction, the multiplanar surface applies forces, the resultant of which is not vertical. This results in non-uniform stress distribution within the tablet as an independent unit which in turn causes tablet capping and the inadequate imprinting or embossing of indicia of any of its surfaces. In addition, the uneven distribution of stresses results in varying levels oflubrication effectiveness of the tablet planes in contact with the press tooling which, in turn, causes picking" of material off the tablet surface. To overcome this phenomenon requires a highly cohesive mixture which is at the same time sufficiently lubricated to enable friction-free tooling to tablet contact on all tablet planes. In practice the tablet formulator has to balance the lubricant level against the binder level because the increase of the former will diminish the effect of the latter until the critical region of such action is surpassed.
Picking" and sticking are words of art, meaning part of the tablet sticks to the tips of the upper or lower punch. Capping describes a condition in which the tablet laminates into one or more layers.
This invention has been directed principally to the application of specific pharmaceutical formulations incorporating isosorbide dinitrate as the active ingredient, but is applicable to other deeply grooved tablets as well. lsosorbide dinitrate is a potent coronary vasodilator.
It was originally presumed that existing, acceptable, direct compression, tableting compositions could be adequately compressed with deep scoring tooling. Two such compositions were evaluated and surprisingly, it was found that acceptable tablets could not be made. Using a placebo composition (one without an active ingredient) similar to a presently used acceptable isosorbide dinitrate tablet composition, it was determined that, unexpectedly, a total tablet weight was critical to obtain acceptable tablets. To minimize the problems caused by stress non-uniformity, an optimal weight was found where after sufficient compression the distance between the apex of the convex side of the tablet and the bottom of the V-shaped opening on top will be minimal while still allowing for adequate manufacturability.
Having established the critical tablet weight, it was expected that compositions containing the active ingredient would tablet in an acceptable manner because acceptable tablets could be made at this composition using conventional tools. However, unexpectedly, it was found that a critical binder-lubricant relationship was needed to produce acceptable tablets with deep scoring tooling.
Four experiments were designed to select the most optimal tablet weight for the easy-break design. The data is shown in Example I.
EXAMPLE 1 TOTAL TABLET WEIGHT OPTIMIZATION All experiments were run in duplicates from one stock powder mixture and directly compressed on a rotary tablet press. The material run was an optimal placebo mixture 88 des ri d below? order to resolve the problem a set of experiments was FORMLFLAE. A B C D Lactose hydrous U.S.P. qs qs qs qs Microcrystalline Cellulose 25 W 25 Wk) 25 w/o 25 w/o Magnesium Stcarate USP. 0.25 w/o 0.25 w/o 0.25 w/o 0.25 w/o Total Tablet Weight 230 mg 200 mg 175 mg l50 mg designed to determine the critical nature of the binder and lubricant levels. The experiments are shown in Example ll:
EXAMPLE ll Following the procedure of Example I a series of formulations were prepared and deeply scored tablets were made from them. The formulations are shown in Table l.
TABLE I PERCENT OF TOTAL TABLET WEIGHT FORMULA A B C D E F g H l J K Microcrystalline Cellulose 25 25 25 45 45 25 25 25 60 'Solkafloc l0 Lactose. hydrous s qs qs qs qs qs qs qs qs qs Lactose. anhydrous 63 Dicalcium Phosphate Sta-Rx I500 74 Magnesium Stcaratc 0.22 0.3 0.22 0.22 0.3 0.22 0.35 0.3 0.3 0.4 0.35 Stcaric Acid "Stcro-Tex 0.50 Tale 2 lsosorbide Dinitrate Trituration 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 200 mg mg mg mg mg mg mg mg mg mg mg Total Weight mg 175 I75 175 175 175 175 175 I75 I75 175 175 Formulas A through H with the exception of G did not exhibit adequate manufacturahility in a direction compression process.
I) Purified Cellulose, Brown Co. 1 Directly compressible starch 1"! Edible vegetable oil. powdered iubricunl FORMULA C: Produced satisfactory tablet hardness of 8-l4 s.c.u. and friability of 0.0% at that range. FORMULA D: Produced satisfactory tablets.
Initially it was tried to utilize a conventional isosorbide dinitrate formula and weight for the easy-break tableting tools. It was expected that the design would perform adequately at a total weight of 230 milligrams (mg). Surprisingly the tablets made at this weight were unsatisfactory. and evidenced capping, high friability in addition to insufficient tablet hardness. An attempt was made to solve the problem by selecting the most adequate tablet weight to achieve better manufacturability, but was unsuccessful The weight selection experiments indicated that in order to achieve adequate tableting parameters with deep scoring tooling the tablet weight will have to be under 200 mg. The optimum weight is about 175 mg because at 150 mg there is a high probability of tooling contact which in turn may cause damage to the punch tips.
Once the weight problem was solved. no further problems were anticipated. However, upon careful scrutiny of the tableting performance there was found an unexpected problem in the binder and lubricant relationship. "Picking" and *sticking" were found in some cases and soft tablets with capping in others. in
FORMULA B contained the minimal level of anhydrous lactose to produce an adequate tablet. However, the tablet demonstrated poor disintegration.
FORMULA C produced soft tablets that capped while still picking.
FORMULA D exhibited insufficient hardness range and picking on both tablet faces.
FORMULA E showed insufficient binding resulting in very soft tablets having high friabilityl FORMULA F showed inadequate performance because of slight pick.
FORMULA G showed adequate manufacturability as to hardness and friability. The tablets were free of pick ing.
FORMULA H showed insufficient hardness with picking on bottom face.
cause the design of a chewable tablet requires the incorporation of a chewable carrier, it was necessary to evaluate different chewable materials to obtain a sufficiently cohesive and well lubricated direct compression formula. The data obtained in those experiments is 5 FORMULA 1 was a siugged f m which cxhibied shown in Table 11 m which the tablets were prepared as binding and picking on the tablet lower face. described in Example 1.
TABLE 11 CHEWABLE TABLETS FORMLFLAE A B C D E F G H lsosorbide Dinitratc (25%] 40 mg 40 mg 40 mg 40.0 mg 40 mg 40 mg 40.0 mg 40.0 mg Lactose mixture *Nutah qs qs Mannitol U.S.P. qs 20% 20% qs *Cellutab. anhydrous 31.5% 31.5% 31.5% qs Microcrystalline Cellulose 25.0% 20% 25% 25% 25% 20)? Solka floc 810% Magnesium Stearate use 0.6% 0.7% 1.0% 1.0% 0.5% 0.9% 0.-J%+0.9% 0.35% FD&C Yellow No. 5 Lake 01')? 0.1% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% Sodium Saccharine NF. 0.08% 0.08% 0.08% 0.08% Methyl Cellulose 400 cps 07% Lemon Oil. spray dried 1.7% 1.7% 1.7% 1.7% 1.7%
1.7% Total Tablet Weight 222.5 196 190 175.0 175 175 175.0 175 mg mg mg mg mg mg mg mg Sucrose. invert sugar, starch. magnesium stearate direct compression granulation.
"Dextrose and corn syrup solids granulation FORMULA J was a slugged formula with a higher lubricant level which produced adequate lubrication but insufficient hardness.
FORMULA K showed excellent manufacturability for all parameters.
Based on the foregoing it was determined that tablets made of conventional pharmaceutical ingredients would manufacture adequately at weights under 200 mg. utilizing a deeply scored design. In addition, a great amount of experimentation and design was spent on the tablet formulation to overcome the critical nature of its binder and lubricant dependence From the foregoing the preferred weight for deeply grooved tablets is 150 to 175 mg. The preferred ratio of lubricant to binder is obtained when the binder constitutes 45 to 99.7 w/o and the lubricant constitutes 0.3 to 0.4 w/o of tablet exclusive of the amount of the active ingredient, fillers, extenders. flavor and the like. That is, the weight per cent of the binder and lubricant is based on the portion of the tablet composition usually referred to as q.s.
Only microcrystalline cellulose of the binders presently available on the market has been found to be use ful in deep grooved tablet compositions. Only the stearates. including stearic acid, of the lubricants presently available on the market have been found to be useful in deep grooved tablet compositions.
A particularly advantageous formula weighs 175 mg. per tablet and contains 60 percent by weight microcrystalline cellulose with 0135 percent by weight of magnesium stearate.
For assuring of distintegration and dissolution reproducibility the use of 1 percent Amberlite is optional and has been tested to that effect.
EXAMPLE lll Preparation of 10 mg. lsosorbide Dinitrate Chewable Tablets The deeply scored design was also utilized in the manufacture of a chewable tablet form containing iso sorbide dinitrate at a 10 mg. level.
Again, in this formula it was found necessary to resort to a lower tablet weight of 175 mg. ln addition. be-
Formulae A, B, D. E and F are directly compressed.
Formula A exhibited very high friability. capping and a narrow hardness range.
In Formula B the weight has been reduced, but tablets still exhibit heavy capping and friability with very low hardness.
Formula C was a wet granulated formula, and exhibited high friability, capping and inadequate chewability due to the wet binder.
Formula D shows adequate manufacturability and chewability.
in Formula E reduced lubricant level results in heavy picking on both tablet faces.
1n Formula F eliminating the sweetener from For mula D maintains adequate manufacturability with improved taste.
Formula G was slugged and exhibited capping, narrow hardness range and slight picking.
Formula H produced adequate tableting characteristics.
From the foregoing it was concluded that 10 mg. chewable tablets were successfully made in two formulations:
l. The first formulation uses a directly compressed mannitol and a dextrose and corn syrup solids granulation in combination;
2. The second formulation uses dextrose and corn syrup solids granulation without mannitol in direct compression.
The choice between these two categories depends strictly on personal taste preference. Both formulae will produce similarly adequate results.
The preferred embodiment at which chewable deeply scored tablets can be made is for the first category with at least 20 percent by weight of microcrystallinc cellulose, 31.5 percent by weight of Cellutab anhydrous. 25 percent mannitol and a range of 0.7-1.0 percent by weight of magnesium stearate Jr: at the second category with Cellutab anhydrous and a minimum of 0.35 percent by weight of magnesium stearatc.
The incorporation of an ingredient which would serve as a chewable carrier, one which imparts a cer tain pallatable feeling, sweetness and desirable chewability, presents additional variables to the ones already described above. When processing and formulating for such purpose. it is necessary to consider the properties producing the resulting chewable quality of the tablet. that is hardness, taste and pallatability. The majority of chewable carriers, apart from the granulated natural sugars and their derivatives, do not lend themselves to direct compression and tend to lose some of their taste upon any granulation method.
The examples illustrated in Table II present the compositions of pharmaceutical tablets manufactured by three basic methods: direct compression. dry granulation, and wet granulation. These examples are not to be construed as limiting the scope of this invention which may only be determined by reference to the appended claims.
What is claimed is:
l. A pharmaceutical tablet which is adequately imprinted with indicia or embossing and scored to form a groove which is one-third to two-thirds the depth of the total tablet thickness to facilitate separation into subdivisions containing substantially equal amounts of a pharmaceutically active ingredient comprising a directly compressed formulation of 5 to 10 milligrams of an active ingredient, the remainder being 45 to 99.7 percent by weight of microcrystalline cellulose and 0.3 to 0.4 percent by weight of magnesium stearate, along with fillers. extenders, flavoring and the like.
2. The tablet as defined in claim 1 in which the total tablet weight is [50 to 175 milligrams.
3. A tablet as defined in claim 1 in which the total tablet weight is about l milligrams 4. A tablet as defined in claim 1 in which the microcrystalline cellulose is present in the amount of 60 percent by weight and the magnesium stearate is present in the amount of 0.35 percent by weight.
5. A tablet as defined in claim 1 in which the active ingredient is S to 10 milligrams of isosorbide dinitratev i
Claims (5)
1. A PHARMACEUTICAL TABLET WHICH IS ADEQUATELY IMPRINTED WITH INDICIA OR EMBOSING AND SCORED TO FORM A GROOVE WHICH IS ONE-THIRD TO TWO-THIRDS THE DEPTH OF THE TOTAL TABLET THICKNES TO FACTILITATE SEPARATION INTO SUBDIVISIONS CONTAINING SUBSTANTIALLY EQUAL AMOUNTS OF A PHARMACEUTICALLY ACTIVE INGREDIENT COMPRISING A DIRECTLY COMPRESSED FORMULATION OF 5 TO 10 MILLIGRAMS OF AN ACTIVE INGREDIENT, THE REMAINDER BEING 45 TO 99.7 PERCENT BY WEIGHT OF MICROCRYSTALLINE CELLULOSE AND 0.3 TO 0.4 PERCENT BY WEIGHT OF MAGNESIUM STEARATE, ALONG WITH FILLERS, EXTENDERS, FLAVORING AND THE LIKE.
2. The tablet as defined in claim 1 in which the total tablet weight is 150 to 175 milligrams.
3. A tablet as defined in claim 1 in which the total tablet weight is about 175 milligrams.
4. A tablet as defined in claim 1 in which the microcrystalline cellulose is present in the amount of 60 percent by weight and the magnesium stearate is present in the amount of 0.35 percent by weight.
5. A tablet as defined in claim 1 in which the active ingredient is 5 to 10 milligrams of isosorbide dinitrate.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US312469A US3883647A (en) | 1972-12-06 | 1972-12-06 | Tablet formulation |
US529423A US3927194A (en) | 1972-12-06 | 1974-12-04 | Tablet formulation |
US05/666,559 USRE29077E (en) | 1972-12-06 | 1976-03-15 | Tablet formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US312469A US3883647A (en) | 1972-12-06 | 1972-12-06 | Tablet formulation |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US05/666,559 Reissue USRE29077E (en) | 1972-12-06 | 1976-03-15 | Tablet formulation |
US05/666,560 Division USRE29076E (en) | 1974-12-04 | 1976-03-15 | Tablet formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US3883647A true US3883647A (en) | 1975-05-13 |
Family
ID=23211601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US312469A Expired - Lifetime US3883647A (en) | 1972-12-06 | 1972-12-06 | Tablet formulation |
Country Status (1)
Country | Link |
---|---|
US (1) | US3883647A (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4215104A (en) * | 1979-03-26 | 1980-07-29 | Mead Johnson & Company | Multi-fractionable tablet structure |
FR2452284A1 (en) * | 1979-03-26 | 1980-10-24 | Bristol Myers Co | MULTIPLE-ELEMENT FRACTIONABLE SHELF STRUCTURE |
WO1981002521A1 (en) * | 1980-03-10 | 1981-09-17 | Mendell Co Inc Edward | Pharmaceutical vehicle composition and process of producing same |
US4376111A (en) * | 1980-12-04 | 1983-03-08 | Smith Kline & French Laboratories Limited | Tilting units |
DK153772B (en) * | 1979-08-16 | 1988-09-05 | Ciba Geigy Ag | DIVIDABLE TABLE WITH RETARD EFFECT |
US4863741A (en) * | 1985-03-25 | 1989-09-05 | Abbott Laboratories | Tablet composition for drug combinations |
US4874614A (en) * | 1985-03-25 | 1989-10-17 | Abbott Laboratories | Pharmaceutical tableting method |
US5066441A (en) * | 1980-12-12 | 1991-11-19 | Rhone-Poulenc Basic Chemicals Co. | Process for compacting a calcium phosphate composition |
US5520929A (en) * | 1991-09-10 | 1996-05-28 | Takeda Chemical Industries, Ltd. | Divisible tablet |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US20030169769A1 (en) * | 2002-03-08 | 2003-09-11 | Texas Instruments Incorporated | MAC extensions for smart antenna support |
US20060165635A1 (en) * | 2002-11-28 | 2006-07-27 | Kelly Robert J | Personal care formulations containing keratin |
WO2006099309A2 (en) * | 2005-03-11 | 2006-09-21 | Keratec Ltd. | Keratin and soluble derivatives thereof for treating oxidative stress and inflammation and promoting skin health |
US20080004423A1 (en) * | 2003-09-19 | 2008-01-03 | Robert James Kelly | Composite Materials Containing Keratin |
US20080038327A1 (en) * | 2003-12-19 | 2008-02-14 | Robert James Kelly | Wound Care Products Containing Keratin |
US20080039951A1 (en) * | 2002-06-10 | 2008-02-14 | Keratec Limited | Orthopaedic materials derived from keratin |
US20080206301A1 (en) * | 2006-12-06 | 2008-08-28 | Robert James Kelly | Bone void fillers and methods of making the same |
US7465321B2 (en) | 2001-08-31 | 2008-12-16 | Keratec Limited | Production of biopolymer film, fibre, foam and adhesive materials from soluble S-sulfonated keratin derivatives |
US20080317826A1 (en) * | 2007-05-24 | 2008-12-25 | Robert James Kelly | Porous keratin constructs, wound healing assemblies and methods using the same |
US20090105456A1 (en) * | 2006-12-11 | 2009-04-23 | Robert James Kelly | Porous keratin construct and method of making the same |
US20090111750A1 (en) * | 2007-10-31 | 2009-04-30 | Keratec, Ltd. | Keratin derivatives and methods of making the same |
US20100086591A1 (en) * | 2006-09-15 | 2010-04-08 | Murachanian Dennis C | Rapidly Disintegrating Dosage Form |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1836604A (en) * | 1929-06-01 | 1931-12-15 | Simon M Meyer | Sugar unit |
US3146168A (en) * | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
US3336200A (en) * | 1963-05-28 | 1967-08-15 | Warner Lambert Pharmaceutical | Tablet structure |
US3723614A (en) * | 1971-01-06 | 1973-03-27 | Ciba Geigy Ag | Maltese-cross scored tablet |
-
1972
- 1972-12-06 US US312469A patent/US3883647A/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1836604A (en) * | 1929-06-01 | 1931-12-15 | Simon M Meyer | Sugar unit |
US3146168A (en) * | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
US3336200A (en) * | 1963-05-28 | 1967-08-15 | Warner Lambert Pharmaceutical | Tablet structure |
US3723614A (en) * | 1971-01-06 | 1973-03-27 | Ciba Geigy Ag | Maltese-cross scored tablet |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4215104A (en) * | 1979-03-26 | 1980-07-29 | Mead Johnson & Company | Multi-fractionable tablet structure |
FR2452284A1 (en) * | 1979-03-26 | 1980-10-24 | Bristol Myers Co | MULTIPLE-ELEMENT FRACTIONABLE SHELF STRUCTURE |
US4258027A (en) * | 1979-03-26 | 1981-03-24 | Mead Johnson & Company | Multi-fractionable tablet structure |
DK153772B (en) * | 1979-08-16 | 1988-09-05 | Ciba Geigy Ag | DIVIDABLE TABLE WITH RETARD EFFECT |
WO1981002521A1 (en) * | 1980-03-10 | 1981-09-17 | Mendell Co Inc Edward | Pharmaceutical vehicle composition and process of producing same |
US4376111A (en) * | 1980-12-04 | 1983-03-08 | Smith Kline & French Laboratories Limited | Tilting units |
US5066441A (en) * | 1980-12-12 | 1991-11-19 | Rhone-Poulenc Basic Chemicals Co. | Process for compacting a calcium phosphate composition |
US4863741A (en) * | 1985-03-25 | 1989-09-05 | Abbott Laboratories | Tablet composition for drug combinations |
US4874614A (en) * | 1985-03-25 | 1989-10-17 | Abbott Laboratories | Pharmaceutical tableting method |
US5520929A (en) * | 1991-09-10 | 1996-05-28 | Takeda Chemical Industries, Ltd. | Divisible tablet |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US6126969A (en) * | 1996-02-27 | 2000-10-03 | L. Perrigo Company | Immediate release/sustained release compressed tablets |
US7465321B2 (en) | 2001-08-31 | 2008-12-16 | Keratec Limited | Production of biopolymer film, fibre, foam and adhesive materials from soluble S-sulfonated keratin derivatives |
US20030169769A1 (en) * | 2002-03-08 | 2003-09-11 | Texas Instruments Incorporated | MAC extensions for smart antenna support |
US7892572B2 (en) | 2002-06-10 | 2011-02-22 | Keraplast Technologies, Ltd. | Orthopaedic materials derived from keratin |
US20080039951A1 (en) * | 2002-06-10 | 2008-02-14 | Keratec Limited | Orthopaedic materials derived from keratin |
US20060165635A1 (en) * | 2002-11-28 | 2006-07-27 | Kelly Robert J | Personal care formulations containing keratin |
US7767756B2 (en) | 2003-09-19 | 2010-08-03 | Keraplast Technologies, Ltd. | Composite materials containing keratin |
US20080004423A1 (en) * | 2003-09-19 | 2008-01-03 | Robert James Kelly | Composite Materials Containing Keratin |
US7732574B2 (en) | 2003-12-19 | 2010-06-08 | Keraplast Technologies, Ltd. | Wound care products containing keratin |
US20080038327A1 (en) * | 2003-12-19 | 2008-02-14 | Robert James Kelly | Wound Care Products Containing Keratin |
US7579317B2 (en) | 2005-03-11 | 2009-08-25 | Keratec, Ltd. | Nutraceutical composition comprising soluble keratin or derivative thereof |
US20070065506A1 (en) * | 2005-03-11 | 2007-03-22 | Kelly Robert J | Keratin and soluble derivatives thereof for a nutraceutical and to reduce oxidative stress and to reduce inflammation and to promote skin health |
WO2006099309A3 (en) * | 2005-03-11 | 2006-12-07 | Keratec Ltd | Keratin and soluble derivatives thereof for treating oxidative stress and inflammation and promoting skin health |
WO2006099309A2 (en) * | 2005-03-11 | 2006-09-21 | Keratec Ltd. | Keratin and soluble derivatives thereof for treating oxidative stress and inflammation and promoting skin health |
US20100086591A1 (en) * | 2006-09-15 | 2010-04-08 | Murachanian Dennis C | Rapidly Disintegrating Dosage Form |
US8142807B2 (en) | 2006-12-06 | 2012-03-27 | Keraplast Technologies, Ltd. | Bone void fillers and methods of making the same |
US20080206301A1 (en) * | 2006-12-06 | 2008-08-28 | Robert James Kelly | Bone void fillers and methods of making the same |
US8124735B2 (en) | 2006-12-11 | 2012-02-28 | Keraplast Technologies, Ltd. | Porous keratin construct and method of making the same |
US20090105456A1 (en) * | 2006-12-11 | 2009-04-23 | Robert James Kelly | Porous keratin construct and method of making the same |
US20080317826A1 (en) * | 2007-05-24 | 2008-12-25 | Robert James Kelly | Porous keratin constructs, wound healing assemblies and methods using the same |
US20090111750A1 (en) * | 2007-10-31 | 2009-04-30 | Keratec, Ltd. | Keratin derivatives and methods of making the same |
US10500162B2 (en) | 2014-10-31 | 2019-12-10 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10111839B2 (en) | 2014-10-31 | 2018-10-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10292938B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10292939B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10449159B2 (en) | 2014-10-31 | 2019-10-22 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10507186B2 (en) | 2014-10-31 | 2019-12-17 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512612B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512613B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10568841B2 (en) | 2014-10-31 | 2020-02-25 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10688060B2 (en) | 2014-10-31 | 2020-06-23 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US11896722B2 (en) | 2014-10-31 | 2024-02-13 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3883647A (en) | Tablet formulation | |
US3927194A (en) | Tablet formulation | |
EP0997143B1 (en) | Soft chewable tablets | |
EP0914818B1 (en) | Intraorally rapidly disintegrable tablet | |
US5501861A (en) | Fast dissolving tablet and its production | |
US3336200A (en) | Tablet structure | |
US8945618B2 (en) | Intrabuccally rapidly disintegrating tablet and a production method of the tablets | |
US6277409B1 (en) | Protective coating for tablet | |
EP1153616B1 (en) | Tablets quickly disintegrated in the oral cavity | |
US5609883A (en) | Compressed tablet transitory lubricant system | |
US20020122823A1 (en) | Soft tablet containing dextrose monohydrate | |
US3632778A (en) | Tablets containing l-dopa | |
FI945452A (en) | Effervescent medicinal product containing ibuprofen and method of manufacture | |
EP0454396A1 (en) | Tablet composition and method for problem pharmaceutical materials | |
USRE29077E (en) | Tablet formulation | |
US20030026835A1 (en) | Tablets disintegrating rapidly in the oral cavity | |
USRE29076E (en) | Tablet formulation | |
CA2341005C (en) | Exactly divisible tablet | |
US3395211A (en) | Tableting process | |
NO128051B (en) | ||
JP2000044463A (en) | Rapidly dissolvable tablet | |
AU2010270976B2 (en) | Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen | |
GB2353933A (en) | Compositions comprising trehalose for forming tablets | |
EP0975337A2 (en) | Fast release compressed tablet of flurbiprofen | |
JPS5344617A (en) | Drug composition |